SeQuent Scientific Ltd
SEQUENTSeQuent Scientific Ltd
SEQUENTPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
308.96 | 7.14 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 621.08 | 694.65 | 1,292.62 | 1,047.98 | 1,189.33 | 1,369.98 | 1,423.67 | 1,427.30 | 1,395.45 | 1,467.89 | ||||||||||
Raw Materials | 293.07 | 366.89 | 486.44 | 570.52 | 600.59 | 733.68 | 842.41 | 814.87 | 789.20 | 1,322.88 | ||||||||||
Power & Fuel Cost | 26.51 | 12.77 | 14.66 | 23.06 | 24.73 | 28.75 | 33.86 | 42.45 | 35.46 | |||||||||||
Employee Cost | 86.67 | 106.22 | 113.83 | 145.95 | 165.06 | 187.22 | 231.37 | 258.39 | 250.57 | |||||||||||
Selling & Administrative Expenses | 55.11 | 74.68 | 94.72 | 90.93 | 108.27 | 115.85 | 132.65 | 139.02 | 138.35 | |||||||||||
Operating & Other expenses | 89.67 | 82.59 | 64.28 | 83.92 | 110.27 | 92.86 | 63.12 | 219.02 | 126.88 | |||||||||||
EBITDA | 70.05 | 51.50 | 518.69 | 133.60 | 180.41 | 211.62 | 120.26 | -46.45 | 54.99 | 145.01 | ||||||||||
Depreciation/Amortization | 45.72 | 40.07 | 41.34 | 41.92 | 50.62 | 50.60 | 51.54 | 55.69 | 61.54 | 65.29 | ||||||||||
PBIT | 24.33 | 11.43 | 477.35 | 91.68 | 129.79 | 161.02 | 68.72 | -102.14 | -6.55 | 79.72 | ||||||||||
Interest & Other Items | 38.15 | 28.34 | 33.07 | 32.80 | 35.71 | 24.38 | 15.77 | 35.52 | 48.09 | 55.69 | ||||||||||
PBT | -13.82 | -16.91 | 444.28 | 58.88 | 94.08 | 136.64 | 52.95 | -137.66 | -54.64 | 24.03 | ||||||||||
Taxes & Other Items | 4.65 | -3.08 | 22.72 | 10.22 | 24.17 | 41.19 | 11.98 | -16.50 | -18.77 | 7.56 | ||||||||||
Net Income | -18.47 | -13.83 | 421.56 | 48.66 | 69.91 | 95.45 | 40.97 | -121.16 | -35.87 | 16.47 | ||||||||||
EPS | -0.34 | -0.53 | 15.98 | 1.91 | 2.82 | 3.84 | 1.65 | -4.87 | -1.44 | 0.66 | ||||||||||
DPS | 0.00 | 0.00 | 0.18 | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.01 | 0.10 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
SeQuent Scientific Ltd | -141.86 | 7.14 | — |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare SEQUENT with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.59%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.73%
Top 5 Mutual Funds holding SeQuent Scientific Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 8.5060% | Percentage of the fund’s portfolio invested in the stock 1.59% | Change in the portfolio weight of the stock over the last 3 months 0.81% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/98 (+3) |
Quant Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5379% | Percentage of the fund’s portfolio invested in the stock 6.23% | Change in the portfolio weight of the stock over the last 3 months 1.91% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/27 (+5) |
UTI Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3996% | Percentage of the fund’s portfolio invested in the stock 1.69% | Change in the portfolio weight of the stock over the last 3 months 0.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/44 (+4) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995 equity shares of Rs. 2/- each.Powered by Capital Market - Live
Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live
Sequent Scientific has allotted 60,000 equity shares under ESOP on 16 October 2024. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 49,91,63,990/-consisting of 249581995 Equity Shares of Rs. 2/- each to Rs. Rs. 49,92,83,990/-consisting of 249641995 Equity Shares of Rs. 2/- each.Powered by Capital Market - Live
Force Motors Ltd, Dynamatic Technologies Ltd, Balrampur Chini Mills Ltd and Shree Renuka Sugars Ltd are among the other gainers in the BSE's 'A' group today, 27 September 2024.Sequent Scientific Ltd spiked 17.44% to Rs 223.6 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 13.31 lakh shares were traded on the counter so far as against the average daily volumes of 2.67 lakh shares in the past one month. Force Motors Ltd soared 7.97% to Rs 7516.15. The stock was the second biggest gainer in 'A' group. On the BSE, 21141 shares were traded on the counter so far as against the average daily volumes of 4192 shares in the past one month. Dynamatic Technologies Ltd surged 7.92% to Rs 7976. The stock was the third biggest gainer in 'A' group. On the BSE, 3071 shares were traded on the counter so far as against the average daily volumes of 2631 shares in the past one month. Balrampur Chini Mills Ltd rose 7.84% to Rs 660.55. The stock was the fourth biggest gainer in 'A' group. On the BSE, 3.69 lakh shares were traded on the counter so far as against the average daily volumes of 1.07 lakh shares in the past one month. Shree Renuka Sugars Ltd added 7.83% to Rs 51.89. The stock was the fifth biggest gainer in 'A' group. On the BSE, 61.14 lakh shares were traded on the counter so far as against the average daily volumes of 11.33 lakh shares in the past one month. Powered by Capital Market - Live
Sequent Scientific announced that the Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live
Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using our API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. The WHO prequalification recognizes Sequent Scientific's commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality. The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,' said Rajaram Narayanan, MD & CEO of Sequent Scientific.Powered by Capital Market - Live
This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. Rajaram Narayanan, MD & CEO of Sequent Scientific, said, 'The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale.' Sequent Scientific is a global pharmaceutical company specializing in Animal Health. With a strong international presence, the company operates in both API and formulation domains. Their focus lies in addressing unmet market needs for livestock, poultry, and companion animals. The company reported net profit of Rs 6.51 crore in Q1 FY25 as compared with net loss of Rs 34.85 crore in Q1 FY24. Net sales jumped 17.1% YoY to Rs 390.21 crore during the quarter. The counter hit 52-week high at Rs 175 in intraday today.Powered by Capital Market - Live
Net profit of Sequent Scientific reported to Rs 6.51 crore in the quarter ended June 2024 as against net loss of Rs 34.85 crore during the previous quarter ended June 2023. Sales rose 17.11% to Rs 390.21 crore in the quarter ended June 2024 as against Rs 333.21 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales390.21333.21 17 OPM %10.75-2.47 - PBDT28.25-17.93 LP PBT12.00-32.17 LP NP6.51-34.85 LP Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.48% to 0.37%